| Name | Title | Contact Details |
|---|
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.
Spun out of MIT in 2006, Cambrian Innovation is commercializing a portfolio of environmental solutions based on newly discovered electrically active microbes. By harnessing the power of bio-electricity and advances in electrochemistry, Cambrian Innovation`s products help industrial, agricultural, and government customers save money while recovering clean water and clean energy from wastewater streams. Our bio-electrogenic sensor platform enables low-cost, real-time monitoring of critical natural resources. At Cambrian Innovation our vision is simple: Industry is an ecosystem. Because the biological world is by definition sustainable, creative application of biological engineering is the best way to solve our most pressing environmental challenges. Cambrian Innovation`s solutions leverage advances in bio-electricity to help industrial and agricultural customers cut costs while meeting their environmental goals.
ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs.
SiChuan Sanherb Biotech is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quantapore`s novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases.